Introduction
============

ATS/IDSA \[[@B1]\] guidelines recommend consideration of local microbiologic data when selecting empiric treatment for ventilator-associated pneumonia (VAP) and broad-spectrum empiric therapy for patients with pneumonia caused by MDR pathogens. The purpose was to use local microbiologic data to develop institution-specific guidelines for VAP.

Methods
=======

We prospectively recorded local microbiologic and susceptibility data in our ICU. Respiratory specimens were tracheal aspirates in all cases and were evaluated by quantitative criteria.

Results
=======

We had 40 episodes (2,247 ventilator-days) of VAP (40/133 patients) and 45 isolates. In early-onset pneumonia (≤5 days, eight episodes, three with two isolates): six *Acinetobacter baumannii*: meropenem, colistin, gentamicin (five); three *Pseudomonas aeruginosa*: piperacillin, aztreonam, imipenem, ceftazidime, colistin, ciprofloxacin, cefepime, meropenem, aminoglycosides; one *Klebsiella pneumoniae*: meropenem, colistin, tetracycline; Fungi 1: no susceptibility results. In late-onset pneumonia (\>5 days, 32 episodes, two with two isolates): 25 *A. baumannii*: four to amoxicillin-clavulanic, ceftazidime, piperacillin-tazobactam, aztreonam, imipenem, colistin, ciprofloxacin, cefepime, meropenem, aminoglycosides, 19 to meropenem, gentamicin, colistin, tetracycline and two to colistin; four *P. aeruginosa*: two to piperacillin-tazobactam, two to colistin; one *K. pneumoniae*: piperacillin-tazobactam, aztreonam, imipenem, ceftazidime, colistin, ciprofloxacin, cefepime, meropenem, aminoglycosides, amoxicillin-clavulanic; Fungi 1: no susceptibility results and three unspecified isolates.

Excluding fungi and unspecified isolates, we had 8/45 multisensitive isolates and 32/45 isolates sensitive to colistin (32), meropenem (26) and gentamicin (21). According to these data in early and late VAP the most adequate therapeutic combination to cover possible pathogens is meropenem + colistin. Using this combination we cover all possible pathogens and then de-escalate according to susceptibility results. Following the ATS/IDSA guidelines we would cover only 8/45 isolates.

Conclusion
==========

ATS/IDSA \[[@B1]\] guidelines may not be applicable in all institutions or countries and thus clinicians should incorporate local microbiologic data into institution-specific guidelines \[[@B2]\].
